Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial

Purpose Limited evidence exists on the impact of hormone receptor (HR) status to counsel HER2-positive early breast cancer patients receiving adjuvant anti-HER2 therapy. Methods ALTTO (BIG 2-06) was an international, intergroup, open-label, randomized phase III trial in HER2-positive early breast ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2019-08, Vol.177 (1), p.103-114
Hauptverfasser:	Lambertini, Matteo, Campbell, Christine, Gelber, Richard D., Viale, Giuseppe, McCullough, Ann, Hilbers, Florentine, Korde, Larissa A., Werner, Olena, Chumsri, Saranya, Jackisch, Christian, Wolff, Antonio C., Vaz-Luis, Ines, Ferreira, Arlindo R., Prat, Aleix, Moreno-Aspitia, Alvaro, Piccart, Martine, Loi, Sherene, de Azambuja, Evandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant treatment Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - therapy Cancer Cancer patients Cancer research Carboplatin Chemotherapy, Adjuvant Clinical Trial Clinical trials Disease Disease-Free Survival ErbB-2 protein Estrogen Estrogens Female Hormones Humans Medical colleges Medical prognosis Medical research Medicine Medicine & Public Health Medicine, Experimental Molecular Targeted Therapy Monoclonal antibodies Oncology Product development Progesterone Progesterone receptors Prognosis Proportional Hazards Models Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - metabolism Receptors, Progesterone - metabolism Risk assessment Risk factors Targeted cancer therapy Trastuzumab Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!